Pfizer Ventures News Today

Nucleome Therapeutics, a leading UK biotech firm that specialises in decoding the dark genome's non-coding DNA regions to develop precision medicines for autoimmune diseases like multiple sclerosis, lupus, and rheumatoid arthritis, purchase LTE research-grade autoclave to assist with research. Click to read more...

HBM Healthcare Investments Ltd Bundesplatz 1, 6300 Zug Invitation to the 23rd Ordinary Shareholders Meeting Monday,...

STC-15 is the first METTL3 inhibitor to enter clinical development Clinical data will include safety, pharmacology, target modulation, and clinical activity CAMBRIDGE, England, May

/PRNewswire/ -- Grey Wolf Therapeutics ("Grey Wolf" or "the company"), a clinical-stage biotechnology company leveraging first-of-its-kind antigen modulation...

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Grey Wolf Therapeutics Closes Oversubscribed $50 Million Series B Financing Expansion, Led by ICG Life Sciences, to Accelerate and Expand First-of-its-Kind Antigen Modulation Technology

Hundreds of policymakers, thought leaders, and politicians are coming together at the R.I. convention center to discuss where Rhode Island fits in a multibillion-dollar industry.

British Patient Capital, the venture capital subsidiary of the British Business Bank, has invested £10m into Curve Therapeutics.

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Curve Therapeutics, a biotech developing an intracellular screening platform addressing complex disease targets, has closed its £40.5 million Series A financing.